Article Versions Notes

Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, et al. Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers. 2019; 11(9):1256. https://doi.org/10.3390/cancers11091256

Takada, Hitomi, Masayuki Kurosaki, Kaoru Tsuchiya, Yasuyuki Komiyama, Jun Itakura, Yuka Takahashi, Hiroyuki Nakanishi, Yutaka Yasui, Nobuharu Tamaki, Chiaki Maeyashiki, and et al. 2019. "Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma" Cancers 11, no. 9: 1256. https://doi.org/10.3390/cancers11091256

Takada, H., Kurosaki, M., Tsuchiya, K., Komiyama, Y., Itakura, J., Takahashi, Y., Nakanishi, H., Yasui, Y., Tamaki, N., Maeyashiki, C., Kaneko, S., Takaura, K., Higuchi, M., Okada, M., Wang, W., Osawa, L., Sekiguchi, S., Hayakawa, Y., Yamashita, K., ... Izumi, N. (2019). Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers, 11(9), 1256. https://doi.org/10.3390/cancers11091256